Omacetaxine Mepesuccinate Patent Expiration
Omacetaxine Mepesuccinate is Used for treating leukemia, specifically chronic myeloid/myelogenous leukemia (CML), including patients resistant to or intolerant of tyrosine kinase inhibitors. It was first introduced by Teva Pharmaceuticals International Gmbh
Omacetaxine Mepesuccinate Patents
Given below is the list of patents protecting Omacetaxine Mepesuccinate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Synribo | US6987103 | Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents | Oct 26, 2026 | Teva Pharms Intl |
| Synribo | US7842687 | Cephalotaxane derivatives and their processes of preparation and purification |
Mar 16, 2019
(Expired) | Teva Pharms Intl |
| Synribo | USRE45128 | Cephalotaxane derivatives and their processes of preparation and purification |
Mar 16, 2019
(Expired) | Teva Pharms Intl |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Omacetaxine Mepesuccinate's patents.
Latest Legal Activities on Omacetaxine Mepesuccinate's Patents
Given below is the list recent legal activities going on the following patents of Omacetaxine Mepesuccinate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Certificate Critical | 04 Apr, 2017 | US6987103 |
| Notice of Final Determination -Eligible | 21 Sep, 2016 | US6987103 |
| PTE Interim Patent Extension filed Critical | 15 Aug, 2016 | US6987103 |
| FDA Final Eligibility Letter Critical | 07 Dec, 2015 | US6987103 |
| transaction for FDA Determination of Regulatory Review Period | 07 May, 2015 | US6987103 |
| transaction for FDA Determination of Regulatory Review Period | 21 Apr, 2015 | US6987103 |
| Second letter to regulating agency to determine regulatory review period | 24 Feb, 2015 | US6987103 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2014 | US6987103 |
| Initial letter Re: PTE Application to regulating agency | 26 Nov, 2013 | US6987103 |
| Patent Term Extension Application under 35 USC 156 Filed | 20 Dec, 2012 | US6987103 |
Omacetaxine Mepesuccinate's Family Patents
